Patents by Inventor R. Keith Frank
R. Keith Frank has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11813339Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical compositions that are administered multiple times to a patient, have a lower impurity profile, a longer shelf life, and are less expensive to prepare.Type: GrantFiled: February 6, 2018Date of Patent: November 14, 2023Assignee: IGL PHARMA, INC.Inventors: Jaime Simon, R. Keith Frank
-
Publication number: 20220409751Abstract: A targeted radiopharmaceutical of chemical Formula I, below, is disclosed wherein Q+3 is a trivalent radioactive isotope ion; M is a proton (H+), an ammonium ion or an alkali metal ion; āgā is a number that is 1 to about 12; the boxed mAb MNPR-101 represents the chemically-bonded humanized mAb MNPR-101; and Y? is an optional anion present in an amount needed to balance the ionic charge. A pharmaceutical composition that comprises a theranostic effective amount of a Formula I targeted radiopharmaceutical dissolved or dispersed in a pharmaceutically acceptable diluent is also disclosed, as are a method for treating and/or diagnosing a mammalian host having a disease, disorder or condition characterized by undesired angiogenesis, tumor growth and/or tumor metastasis. A targeted pro-radiopharmaceutical construct similar to that of Formula I but without the radioisotope (Formula III) is also contemplated.Type: ApplicationFiled: May 20, 2022Publication date: December 29, 2022Applicants: Northstar Medical Technologies, LLC, Monopar Therapeutics IncInventors: Andrew MAZAR, James T. HARVEY, R. Keith FRANK, Jaime SIMON, Jason ROGERS
-
Publication number: 20220378956Abstract: A targeted radiopharmaceutical comprising a targeting species chemically-bonded to a PCTA-chelated Q+3 trivalent radioactive ion of Formula I is disclosed. Six of R1 through R7 are H and the seventh is a reacted functionality, Z, that forms the chemical bond with the targeting species, T. āgā is a number whose average value is 1 to about 12. X1, X2, and X3, are substituent groups that can coordinate to the Q+3 ion and/or help neutralize the ionic charge. Anion Y? is optionally present to balance the ionic charge. A pharmaceutical composition comprising a theranostic effective amount of a targeted radiopharmaceutical of Formula I in a pharmaceutically acceptable diluent is also contemplated, as are a method for treating and/or diagnosing a mammalian host having a disease, disorder or condition characterized by undesired angiogenesis, tumor growth and/or tumor metastasis.Type: ApplicationFiled: May 20, 2022Publication date: December 1, 2022Applicants: Northstar Medical Technologies LLC, Monopar Therapeutics Inc.Inventors: James T. HARVEY, Andrew MAZAR, R. Keith FRANK, Jaime SIMON, Jason ROGERS
-
Publication number: 20220273828Abstract: This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two-part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression or bone marrow ablation.Type: ApplicationFiled: May 21, 2022Publication date: September 1, 2022Applicant: IGL Pharma Inc.Inventors: R. Keith Frank, Jaime Simon, Kelli R. Jay
-
Patent number: 11369700Abstract: This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two-part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression or bone marrow ablation.Type: GrantFiled: May 4, 2020Date of Patent: June 28, 2022Assignee: IGL Pharma Inc.Inventors: R. Keith Frank, Jaime Simon, Kelli R. Jay
-
Publication number: 20210138095Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical compositions that are administered multiple times to a patient, have a lower impurity profile, a longer shelf life, and are less expensive to prepare.Type: ApplicationFiled: February 6, 2018Publication date: May 13, 2021Applicant: IGL Pharma, Inc.Inventors: Jaime Simon, R. Keith Frank
-
Patent number: 10918746Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.Type: GrantFiled: January 27, 2020Date of Patent: February 16, 2021Assignee: IsoTherapeutics Group LLCInventors: David A Wilson, R. Keith Frank, Jaime Simon, Druce K Crump
-
Publication number: 20200261607Abstract: This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two-part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression or bone marrow ablation.Type: ApplicationFiled: May 4, 2020Publication date: August 20, 2020Applicant: IsoTherapeutics Group, LLCInventors: R. Keith Frank, Jaime Simon, Kelli R. Jay
-
Publication number: 20200261494Abstract: This invention relates to a solid veterinary formulation and a method for its oral administration to an animal, especially cats or dogs, to remove fluid overload in the animal by using a mixture of a water-absorbing polymer and solid fat, optionally having one or more supplemental ingredients. The fluid overload is caused by congestive heart failure or renal disease. The polymer is capable of absorbing at least 10 times its weight in physiological saline. The polymer and other waste materials are excreted in the feces.Type: ApplicationFiled: October 30, 2018Publication date: August 20, 2020Applicant: IsoTherapeutics Group LLCInventors: Jaime Simon, R Keith Frank
-
Publication number: 20200155716Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.Type: ApplicationFiled: January 27, 2020Publication date: May 21, 2020Applicant: IsoTherapeutics Group LLCInventors: David A Wilson, R. Keith Frank, Jaime Simon, Druce K Crump
-
Patent number: 10596277Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.Type: GrantFiled: November 17, 2018Date of Patent: March 24, 2020Assignee: IGL Pharma, Inc.Inventors: Jaime Simon, R. Keith Frank, David A. Wilson
-
Patent number: 10583211Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.Type: GrantFiled: May 19, 2017Date of Patent: March 10, 2020Assignee: IsoTherapeutics Group LLCInventors: David A Wilson, R. Keith Frank, Jaime Simon, Druce K Crump
-
Publication number: 20190083661Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.Type: ApplicationFiled: November 17, 2018Publication date: March 21, 2019Applicant: IsoTherapeutics Group, LLCInventors: Jaime Simon, R. Keith Frank, David A. Wilson
-
Patent number: 10172965Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.Type: GrantFiled: October 7, 2014Date of Patent: January 8, 2019Assignee: IGL Pharma, Inc.Inventors: Jaime Simon, R. Keith Frank, David A. Wilson
-
Publication number: 20180104366Abstract: This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression.Type: ApplicationFiled: May 24, 2016Publication date: April 19, 2018Applicant: IsoTherapeutics Group, LLCInventors: R. Keith Frank, Jaime Simon, Kelli R. Jay
-
Publication number: 20170258949Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.Type: ApplicationFiled: May 19, 2017Publication date: September 14, 2017Applicant: IsoTherapeutics Group LLCInventors: David A Wilson, R. Keith Frank, Jaime Simon, Druce K Crump
-
Patent number: 9687574Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.Type: GrantFiled: December 21, 2012Date of Patent: June 27, 2017Assignee: IsoTherapeutics Group LLCInventors: David A Wilson, R. Keith Frank, Jaime Simon, Druce K Crump
-
Publication number: 20160250359Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.Type: ApplicationFiled: October 7, 2014Publication date: September 1, 2016Applicant: IsoTherapeutics Group, LLCInventors: Jaime Simon, R. Keith Frank, David A. Wilson
-
Publication number: 20150023869Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.Type: ApplicationFiled: December 21, 2012Publication date: January 22, 2015Applicant: ISOTHERAPEUTICS GROUP LLCInventors: David A Wilson, R. Keith Frank, Jaime Simon, Druce K Crump
-
Publication number: 20120251442Abstract: This invention provides a safer and more effective treatment for non-intracavitary undesirable tissue masses, especially bone cancer and soft tissue tumors. The method involves the direct administration of a therapeutically-effective dose of a formulated radioisotope composition nearby or directly into the tissue mass. Small volumes of the composition are used. Administration of the dose for bone cancer may be done through a hole or multiple holes created in the bone using a miniature drill. Delivery of the dose directly into a tumor may be accomplished using a microsyringe or a miniature pump capable of accurately delivering microliter amounts of material.Type: ApplicationFiled: May 11, 2012Publication date: October 4, 2012Applicants: GABRIEL INSTITUTE, INC., ISOTHERAPEUTICS GROUP LLCInventors: R. Keith Frank, Kenneth McMillan, Edna Sue McMillian, Jaime Simon, H. Max Loy, JR., Stanley D. Stearns